Dr Martens has reported first half revenue of £322 million, broadly unchanged year on year.

Higher US import tariffs added £2.7 million in costs, with a larger impact expected across the full year, but the company says it will fully mitigate these pressures from FY27 through sourcing flexibility, cost control, and selective pricing in the US.

Gross margin improved and losses narrowed, helped by stronger full price sales and disciplined cost management. Shoe volumes rose 33 percent, and the Americas delivered the strongest growth across regions.

Share this story: